rVA576: Clinical Trials

3 trials of rVA576, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Terminated 1
Phase 11Terminated 1

Follow rVA576: new trials by email Literature Review of rVA576 trials Research Report on rVA576

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
rVA576, Placebo - Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal
Phase 1 / Phase 2TerminatedAKARI Therapeutics122019-03-042025-04-10
rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
rVA576 - Bullous Pemphigoid (BP)
Phase 2CompletedAKARI Therapeutics92018-09-252025-04-22
Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)
Coversin - Paroxysmal Nocturnal Haemoglobinuria (PNH)
Phase 2CompletedAKARI Therapeutics12016-02-012023-07-12

Conditions studied

Conjunctivitis, Allergic (1)  ·  Hemoglobinuria, Paroxysmal (1)  ·  Keratoconjunctivitis (1)  ·  Pemphigoid, Bullous (1)

Sponsors

AKARI Therapeutics (3)

Countries

Netherlands (2)  ·  Germany (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Petra Dr Muus (1)  ·  Sajjad Ahmad (1)  ·  Saskia Dr Langemeijer (1)

Results publications

PMID 31840801, PMID 35507334